 LEXINGTON, Mass., Oct. 12, 2021 GLOBE NEWSWIRE -- Agenus Inc. NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a 20 million cash payment with the dosing of the first patient. 